

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BAMBOOS HEALTH CARE HOLDINGS LIMITED

百本醫護控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2293)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Bamboos Health Care Holdings Limited (the “**Company**”) is pleased to announce that Dr. Leung Wai Cheung (“**Dr. Leung**”) has been appointed as an executive Director of the Company with effect from 1 April 2021.

Dr. Leung, aged 57, is currently the advisor to the executive Board. Dr. Leung was graduated with a Bachelor’s degree of Commerce from the Curtin University of Technology in 1995 and subsequently obtained a Postgraduate Diploma in Corporate Administration in 1998, a Master degree in Professional Accounting from The Hong Kong Polytechnic University in 1999, a Doctor degree of Philosophy in Management from the Empresarial University in 2004, a Doctor degree of Educational Management from the Bulacan State University in 2008, a Doctor degree of Business Administration from European University in 2015 and a Doctor degree of Philosophy in Forensic Accounting and Auditing from Charisma University in 2020.

Dr. Leung has more than 30 years of experience in financial reporting and financial management. He is an adjunct lecturer at the University of Hong Kong School of Professional and Continuing Education, and has been teaching diploma/bachelor/postgraduate/master courses and short courses of professional accounting examinations since 2003. He was the company secretary and financial controller from 2000 to 2011, and an executive director from 2000 to 2003 in FlexSystem Holdings Limited (currently known as Quantum Thinking Limited) (stock code: 8050). He was also the financial controller of Fortune Realty Company Limited from 1996 to 2000, the accounting manager of Wang On Group Limited (stock code: 1222) from 1993 to 1996 and the assistant accountant of Eton Management Limited from 1987 to 1992. He is currently an independent non-executive director of Mobicon Group Limited (stock code: 1213).

Dr. Leung has been an associate member of the Hong Kong Institute of Certified Public Accountants since 1993, CPA Australia since 1996, the Institute of Chartered Secretaries and Administrators since 1997, the Hong Kong Institute of Chartered Secretaries since 1997, the Taxation Institute of Hong Kong since 1998 and the Chartered Professional Accountants of British Columbia, Canada since 2017. He has also been a fellow member of the Association of Chartered Certified Accountants

since 1998 and the Institute of Chartered Accountants in England and Wales since 2017. Dr. Leung joined the Company as the advisor to the executive Board on 1 December 2020, in which he advises the Board on merger and acquisition projects and making investment decisions. Taking into account Dr. Leung's qualifications, working experiences in financial reporting and financial management and as the advisor to the Board, the Board believes that he can provide valuable advice on the direction of the Company's business development.

Dr. Leung has entered into a service agreement with the Company for a term of one (1) year commencing from 1 April 2021 and renewable automatically for successive terms of one (1) year each thereafter, which may be terminated by either party by giving at least one (1) months' prior notice in writing. Dr. Leung will receive from the Company a fixed fee at the annual rate of HK\$960,000 payable by twelve (12) monthly instalments of HK\$80,000 (or a pro rata amount for an incomplete month) together with a year-end bonus at an amount of HK\$80,000 which is determined by the Board upon recommendation from the Remuneration Committee with reference to his qualifications, experience, duties and responsibilities as an executive Director of the Company and prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Dr. Leung (i) has not held any other directorships in any public companies of which the securities are listed on any securities market in Hong Kong or overseas in the past three years; (ii) has not held any other positions in the Company and its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Save as disclosed above, as of the date of this announcement, Dr. Leung has confirmed that there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with his appointment and there is no other information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board takes this opportunity to welcome Dr. Leung to join the Board.

By order of the Board
**Bamboos Health Care
Holdings Limited**
Hai Hiu Chu
Chairman

Hong Kong, 31 March 2021

As at the date of this announcement, the executive Director is Ms. Hai Hiu Chu and the independent non-executive Directors are Dr. Chan Kai Yue Jason, Ms. Chhoa Peck Lim Bella, Dr. Ko Wing Man and Mr. Wong Kon Man Jason.